Aditxt Restructures Note Agreement, Adds New Investor Amid Nasdaq Delisting
ADTX sits 39% above its 52-week low of $0.002 on light trading volume (0.1× avg).
Summary
Aditxt amended its note purchase agreement to add a new investor and cancel an existing note, keeping total principal unchanged. The move comes as the company faces Nasdaq delisting and severe financial strain.
Key Events · Financing and Capital Events · ADTX
-
Note Agreement Amended
Amendment No. 2 to the Note Purchase Agreement dated July 16, 2026, adds Doug Mergenthaler as a new investor and cancels a note held by Cavalry SPV, issuing two new notes of equal aggregate principal amount.
-
Investor Base Restructured
The amendment does not change the total principal amount of the senior secured notes; it replaces one investor with another, maintaining the existing capital structure.
-
Financial Distress Context
Aditxt has been delisted from Nasdaq, reported negative equity and substantial losses in Q1 2026, and recently secured only $500,000 in discounted convertible notes, highlighting severe cash constraints.
-
Secured Obligations
The notes are secured by substantially all assets of Ignite Proteomics and a pledge of Aditxt's equity in Ignite, giving noteholders priority over unsecured creditors.
Analysis · ADTX · Life Sciences
Aditxt amended its senior secured note purchase agreement to bring in a new investor, Doug Mergenthaler, and cancel an existing note held by Cavalry SPV. The total principal amount of the notes remains unchanged, so this is a restructuring of the investor base rather than new capital. However, it comes against a backdrop of severe financial distress — the company has been delisted from Nasdaq, has negative equity, and is burning cash. The ability to attract a new investor to a secured note at this stage is a modest positive signal, but the terms are not disclosed, and the company remains in a precarious position.
At the time of this filing, ADTX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.00 to $31,974.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.